Should Methoxytyramine Routinely Be Included in the Guidelines for Biochemical Assessment of Pheochromocytomas and Paragangliomas?
作者信息
Sweeney Ann T, Blake Michael A, Jasim Sina, Pacak Karel
机构信息
Division of Endocrinology, Department of Medicine, St Elizabeth's Medical Center, Brighton, Massachusetts.
Division of Abdominal Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
出版信息
AACE Clin Case Rep. 2024 Nov 24;11(1):3-4. doi: 10.1016/j.aace.2024.11.005. eCollection 2025 Jan-Feb.
Abstract
摘要
相似文献
1
Should Methoxytyramine Routinely Be Included in the Guidelines for Biochemical Assessment of Pheochromocytomas and Paragangliomas?甲氧基酪胺是否应常规纳入嗜铬细胞瘤和副神经节瘤生化评估指南？
AACE Clin Case Rep. 2024 Nov 24;11(1):3-4. doi: 10.1016/j.aace.2024.11.005. eCollection 2025 Jan-Feb.
2
Cardiovascular events and biochemically negative paragangliomas: a systematic review.心血管事件与生化阴性副神经节瘤：一项系统综述
J Hypertens. 2025 Jul 1;43(7):1116-1125. doi: 10.1097/HJH.0000000000004026. Epub 2025 Apr 3.
3
Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine.产生多巴胺的副神经节瘤的生化和临床表现：血浆甲氧基酪胺的效用
J Clin Endocrinol Metab. 2005 Apr;90(4):2068-75. doi: 10.1210/jc.2004-2025. Epub 2005 Jan 11.
4
Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas.在与SDHD相关的头颈部副神经节瘤患者中通过筛查检测到的嗜铬细胞瘤和肾上腺外副神经节瘤
Endocr Relat Cancer. 2009 Jun;16(2):527-36. doi: 10.1677/ERC-09-0024. Epub 2009 Mar 16.
5
Cabergoline reduces 3-methoxytyramine in a SDHC patient with metastatic paraganglioma and prolactinoma.卡麦角林可降低一名患有转移性副神经节瘤和催乳素瘤的琥珀酸脱氢酶复合物亚基C（SDHC）患者体内的3-甲氧基酪胺水平。
Endocrinol Diabetes Metab Case Rep. 2021 Jun 1;2021. doi: 10.1530/EDM-21-0003.
6
Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas.头颈部副神经节瘤患者 3-甲氧基酪胺的尿排泄增加。
J Clin Endocrinol Metab. 2010 Jan;95(1):209-14. doi: 10.1210/jc.2009-1632. Epub 2009 Nov 6.
7
Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.预测转移性嗜铬细胞瘤和副神经节瘤：基于横断面队列数据的机器学习建模研究。
Lancet Digit Health. 2023 Sep;5(9):e551-e559. doi: 10.1016/S2589-7500(23)00094-8. Epub 2023 Jul 18.
8
Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas.尿3-甲氧基酪胺在筛查分泌多巴胺的嗜铬细胞瘤和副神经节瘤中的低特异性。
Clin Biochem. 2016 Oct;49(15):1205-1208. doi: 10.1016/j.clinbiochem.2016.05.008. Epub 2016 May 18.
9
N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.嗜铬细胞瘤和副神经节瘤的N-糖组分析可区分转移性和非转移性疾病。
J Clin Endocrinol Metab. 2017 Nov 1;102(11):3990-4000. doi: 10.1210/jc.2017-00401.
10
Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients.腹腔镜和后腹腔镜治疗嗜铬细胞瘤及腹膜后副神经节瘤：126例患者161个肿瘤的治疗结果
World J Surg. 2006 May;30(5):899-908. doi: 10.1007/s00268-005-0373-6.
本文引用的文献
1
Dopamine-Secreting Carotid Body Paraganglioma in a Patient With SDHB Mutation.一名携带SDHB突变患者的分泌多巴胺的颈动脉体副神经节瘤
AACE Clin Case Rep. 2024 Mar 12;10(3):109-112. doi: 10.1016/j.aace.2024.03.003. eCollection 2024 May-Jun.
2
Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.SDHB 种系致病性变异患者的嗜铬细胞瘤和副神经节瘤的管理：国际专家共识声明。
Nat Rev Endocrinol. 2024 Mar;20(3):168-184. doi: 10.1038/s41574-023-00926-0. Epub 2023 Dec 14.
3
Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.预测转移性嗜铬细胞瘤和副神经节瘤：基于横断面队列数据的机器学习建模研究。
Lancet Digit Health. 2023 Sep;5(9):e551-e559. doi: 10.1016/S2589-7500(23)00094-8. Epub 2023 Jul 18.
4
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants.临床共识指南：携带 SDHD 种系致病性变异患者的嗜铬细胞瘤和副神经节瘤管理
Lancet Diabetes Endocrinol. 2023 May;11(5):345-361. doi: 10.1016/S2213-8587(23)00038-4. Epub 2023 Mar 31.
5
Biochemical Assessment of Pheochromocytoma and Paraganglioma.嗜铬细胞瘤和副神经节瘤的生化评估。
Endocr Rev. 2023 Sep 15;44(5):862-909. doi: 10.1210/endrev/bnad011.
6
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.2022 年世卫组织副神经节瘤和嗜铬细胞瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):90-114. doi: 10.1007/s12022-022-09704-6. Epub 2022 Mar 13.
7
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine.头颈部副神经节瘤：聚焦肿瘤位置、突变状态和血浆甲氧基酪胺。
Endocr Relat Cancer. 2022 Mar 21;29(4):213-224. doi: 10.1530/ERC-21-0359.
8
New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.嗜铬细胞瘤和副神经节瘤遗传学新见解及其临床意义。
Cancers (Basel). 2022 Jan 25;14(3):594. doi: 10.3390/cancers14030594.
9
Personalized Management of Pheochromocytoma and Paraganglioma.《嗜铬细胞瘤和副神经节瘤的个体化管理》
Endocr Rev. 2022 Mar 9;43(2):199-239. doi: 10.1210/endrev/bnab019.
10
In Matrix Derivatization Combined with LC-MS/MS Results in Ultrasensitive Quantification of Plasma Free Metanephrines and Catecholamines.在基质衍生化结合 LC-MS/MS 的作用下，实现了对血浆游离甲氧基肾上腺素和儿茶酚胺的超灵敏定量分析。
Anal Chem. 2020 Jul 7;92(13):9072-9078. doi: 10.1021/acs.analchem.0c01263. Epub 2020 Jun 12.
Zotero 插件